Background: We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern irstline therapies. Methods: A total of 1,430 patients starting their irst HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and >500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤50 copies/ml) and on the time to virological rebound (irst of two consecutive viraemia values >50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses. Results: Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia >100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was >90% in all pre-HAART viraemia ranges, with the only exception of range >500,000 copies/ml (virological success =83%; P<0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates conirmed this result: patients with pre-HAART viraemia >500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P<0.001). Pre-HAART viraemia >500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P=0.050). Conclusions: At the time of modern HAART, and even though an average >90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with >500,000 copies/ml represent a signiicant population that may deserve special attention.

Impact of pre-therapy viral load on virological response to modern irst-line HAART / M.M. Santoro, D. Armenia, C. Alteri, P. Flandre, A. Calcagno, M. Santoro, C. Gori, L. Fabeni, R. Bellagamba, V. Borghi, F. Forbici, A. Latini, G. Palamara, R. Libertone, V. Tozzi, E. Boumis, C. Tommasi, C. Pinnetti, A. Ammassari, E. Nicastri, A. Buonomini, V. Svicher, M. Andreoni, P. Narciso, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, G.D. Perri, C.F. Perno. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 18:7(2013), pp. 867-876. [10.3851/IMP2531]

Impact of pre-therapy viral load on virological response to modern irst-line HAART

C. Alteri;C.F. Perno
2013

Abstract

Background: We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern irstline therapies. Methods: A total of 1,430 patients starting their irst HAART (genotype-tailored) in 2008 (median; IQR: 2006-2009) were grouped according to levels of pre-HAART viraemia (≤30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 and >500,000 copies/ml). The impact of pre-therapy viraemia on the time to virological success (viraemia ≤50 copies/ml) and on the time to virological rebound (irst of two consecutive viraemia values >50 copies/ml after virological success) were evaluated by Kaplan-Meier curves and Cox regression analyses. Results: Median pre-HAART viraemia was 5.1 log10 copies/ml (IQR 4.5-5.5), and 53% of patients had viraemia >100,000 copies/ml. By week 48, the prevalence of patients reaching virological success was >90% in all pre-HAART viraemia ranges, with the only exception of range >500,000 copies/ml (virological success =83%; P<0.001). Higher pre-HAART viraemia was tightly correlated with longer median time to achieve virological success. Cox multivariable estimates conirmed this result: patients with pre-HAART viraemia >500,000 copies/ml showed the lowest hazard of virological undetectability after adjusting for age, gender, pre-HAART CD4+ T-cell count, transmitted drug resistance, calendar year and third drug administered (adjusted hazard ratio [95% CI]: 0.27 [0.21, 0.35]; P<0.001). Pre-HAART viraemia >500,000 copies/ml was also associated with higher probability of virological rebound compared with patients belonging to lower viraemia strata at weeks 4, 12 and 24 (P=0.050). Conclusions: At the time of modern HAART, and even though an average >90% of virological success, high pre-HAART viraemia remains an independent factor associated with delayed and decreased virological success. Patients starting HAART with >500,000 copies/ml represent a signiicant population that may deserve special attention.
English
Adult; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Risk Factors; Treatment Failure; Treatment Outcome; Viremia; Antiretroviral Therapy, Highly Active; Viral Load
Settore MED/07 - Microbiologia e Microbiologia Clinica
Articolo
Esperti anonimi
Pubblicazione scientifica
2013
International Medical Press
18
7
867
876
10
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
Impact of pre-therapy viral load on virological response to modern irst-line HAART / M.M. Santoro, D. Armenia, C. Alteri, P. Flandre, A. Calcagno, M. Santoro, C. Gori, L. Fabeni, R. Bellagamba, V. Borghi, F. Forbici, A. Latini, G. Palamara, R. Libertone, V. Tozzi, E. Boumis, C. Tommasi, C. Pinnetti, A. Ammassari, E. Nicastri, A. Buonomini, V. Svicher, M. Andreoni, P. Narciso, C. Mussini, A. Antinori, F. Ceccherini-Silberstein, G.D. Perri, C.F. Perno. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 18:7(2013), pp. 867-876. [10.3851/IMP2531]
open
Prodotti della ricerca::01 - Articolo su periodico
29
262
Article (author)
no
M.M. Santoro, D. Armenia, C. Alteri, P. Flandre, A. Calcagno, M. Santoro, C. Gori, L. Fabeni, R. Bellagamba, V. Borghi, F. Forbici, A. Latini, G. Pala...espandi
File in questo prodotto:
File Dimensione Formato  
19.AVT2013.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 243.45 kB
Formato Adobe PDF
243.45 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/803293
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 37
social impact